VOGX NASDAQ
Vogenx Inc.
1W: +2.2%
1M: -12.9%
YTD: +47.4%
$19.16
+1.82 (+10.50%)
Weekly Expected Move ±17.8%
$11
$14
$17
$21
$24
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$284.6M
52W Range12.95-38.41
Volume75,126
Avg Volume166,598
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJames Green
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2026-08-12
Websitevogenx.com
3901 Barrett Drive, Suite 300
Raleigh, NC 27609
US
Raleigh, NC 27609
US
About Vogenx Inc.
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wilkison William | A-Award | 155,000 | $20.05 | 2026-10-02 |
| Toombs Kenneth John | A-Award | 50,000 | $18.23 | 2026-10-02 |
| Pieraccini Peter | A-Award | 50,000 | $18.23 | 2026-10-02 |
| Green James | A-Award | 155,000 | $20.05 | 2026-10-02 |
| DELMAR STEVEN R | A-Award | 155,000 | $18.23 | 2026-10-02 |